GAITHERSBURG, MD--(Marketwire - Sep 11, 2012) - Cytomedix, Inc. (
The AutoloGel System is a device for the production of autologous platelet rich plasma ("PRP") gel, and is the only PRP device cleared by the U.S. Food and Drug Administration ("FDA") for use in wound management.
Posters will be showcased in the Poster Reception September 13 from 5:30 p.m. to 6:15 p.m. local time, and posters will be available for viewing September 12 and September 13 from 8:00 a.m. to 4:00 p.m. local time. The following posters highlighting Cytomedix's PRP technology will be presented at SAWC Fall 2012.
- Aged Spinal Cord Injury Veterans with Recalcitrant Pressure Ulcers Treated with Platelet-Rich Plasma Gel, Natalie Tukpah, RN, CWOCN and Karen Evans, M.D., Veterans Affairs Medical Center, Washington D.C. Poster Number CS-042.
- Healing Complex, Severe Diabetic and Ischemic Wounds in Japan Using Platelet-Rich Plasma Gel, Chugo Rinoie, DPM, ABPO, CWS, Chief of Podiatric Surgery, Wound Healing Center, Methodist Hospital of Southern California, Arcadia, Calif., and Medical Director, Millennia Wound Management, Inc., Los Angeles. Poster Number CR-021.
- Advancing Wound Healing Trajectory with Platelet Rich Plasma Gel in Stalled NPWT Wounds, Janice Wilson, RN, CWOCN and Karl Branch, RN, Asheville Specialty Hospital, Asheville, N.C. Poster Number CR-029.
Cytomedix will host a booth at the Symposium for clinicians and other attendees to learn more about the AutoloGel System and the benefits it provides in the management of complex recalcitrant wounds. Cytomedix will be showcasing AutoloGel at Booth #1007 in the Exhibit Hall.
"SAWC Fall 2012 is the ideal venue to showcase our growing body of positive clinical data on AutoloGel as it is the premier educational wound care program and the largest annual gathering of wound care professionals in the U.S., with more than 1,000 physicians, podiatrists, nurses, therapists and researchers expected to attend," stated Martin P. Rosendale, Chief Executive Officer of Cytomedix. "These poster presentations underscore the robust nature of AutoloGel to advance the speed and progress to healing in a variety of recalcitrant wounds in a number of healthcare settings."
About The Association for the Advancement of Wound Care
Since 1995 the Association for the Advancement of Wound Care ("AAWC") has been the leader in interdisciplinary wound healing and tissue preservation. It is a not-for-profit association headquartered in the U.S. open to everyone involved in wound care, including clinicians, patients and their lay caregivers, facilities, industry, students, retirees and other advocates interested in the care of wounds. AAWC spreads awareness by promoting excellence in education, clinical practice, public policy and research. Through numerous association benefits and activities, AAWC members have the opportunity to be part of a collaborative community that facilitates optimal care for those who suffer with wounds. This community encourages an equal partnership among all individuals who are involved in the care of patients.
For more information about the AAWC and member benefits, please visit www.aawconline.org.
About Cytomedix, Inc.
Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. Our commercial products include the AutoloGel™ System, cleared by the FDA for wound care and the Angel® Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDHbr") technology to isolate a unique, biologically active population of a patient's own stem cells. A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit www.cytomedix.com.
Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's reimbursement related efforts, the Company's ability to capitalize on the benefits of the above-referenced CMS determination, the Company's ability to successfully and favorably conclude the negotiations and related discussions with the above-referenced global pharmaceutical company, the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes," "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2011 and other subsequent filings. These filings are available at www.sec.gov.
Chief Executive Officer
Chief Financial Officer
Anne Marie Fields